Pediatrics
PFAPA
- OVERVIEW: What every practitioner needs to know
-
Are you sure your patient has PFAPA? What are the typical findings for this disease?
-
What other conditions share some of these symptoms?
-
What caused this disease to develop at this time?
-
What laboratory studies should you request to help confirm diagnosis? How should you interpret the results?
-
Would imaging studies be helpful? If so, which ones?
-
If you are able to confirm that the patient has PFAPA, what treatment should be initiated?
-
What are the adverse effects associated with each treatment option?
-
What are the possible outcomes of PFAPA?
-
What causes PFAPA and how frequent is it?
-
How do pathogens/genes/exposure cause the disease?
-
Other clinical manifestations that might help with diagnosis and management
-
What complications might you expect from the disease or treatment of the disease?
-
Are additional laboratory studies available; even some that are not widely available?
-
How can PFAPA be prevented?
-
What is the evidence?
-
Ongoing controversies regarding etiology, diagnosis, treatment
OVERVIEW: What every practitioner needs to know
Are you sure your patient has PFAPA? What are the typical findings for this disease?
PFAPA (periodic fever with aphthous stomatitis, pharyngitis and adenitis) is considered one of the periodic fever syndromes (PFS), which are autoinflammatory diseases characterized by inappropriate, uncontrolled and often spontaneous inflammation in the absence of autoimmunity or infection.
PFAPA is a benign, nonhereditary, self-limited disease in young children between 2-5 yr of age charactized by episodes of sustained fever of 39°C-40.5°C lasting for 3-5 days that recur every 4-6 weeks. Between febrile episodes, patients are asymptomatic and have normal growth and development.
There is often a brief prodrome with lethargy prior to the abrupt onset of fevers, which respond poorly to antipyretics. Associated symptoms include :
Shallow oral ulcers (65-75% patients).
Non-streptococcal pharyngitis (65-75%)
Cervical adenopathy (75-85%).
Arthritis and gastrointestinal manifestations are not seen.
During flares: wbc 10,000-15,000/mm3 with mild neutrophila, thrombocytosis (usually <400,000/mm3) and mild to moderately increased ESR (<60).
Hemoglobin, urinalysis, liver function tests and serum immunoglobulins are unaffected.
Acute phase response resolves between fever episodes.
Mean duration of disease is 4.5 yr; attacks end by 10 yr of age in 90% patients; rare in adults.
Fevers decrease in frequency over time and eventually resolve completely.
What other conditions share some of these symptoms?
Cyclic neutropenia
Fever of unknown origin
HIV/AIDS
Tuberculosis, CMV, brucellosis, rat-bite fever, relapsing fever or other chronic viral, bacterial or parasitic infections
Systemic lupus erythematosus, relapsing polychondritis
ANCA-mediated vasculitis, including Wegener's granulomatosis and microscopic polyangiitis
Takayasu's arteritis
Other systemic autoinflammatory diseases*
HLA B27-associated juvenile spondyloarthropathies
Sarcoidosis
Malignancies, including leukemia and lymphoma
Autoimmune lymphoproliferative syndrome (ALPS)
Acute intermittent porphyria
Surgical emergencies, including appendicitis, intussusception
Relapsing pancreatitis
*Other systemic autoinflammatory syndromes that mimic PFAPA:
Systemic onset juvenile idiopathic arthritis, adult Still's disease
Pyogenic sterile arthritis, pyoderma gangrenosum, and acne syndrome (PAPA)
Chronic granulomatous synovitis with uveitis and cranial neuropathy (Blau syndrome)
Behcet's disease
Crohn's disease
Macrophage activation syndrome
Hereditary or acquired angioedema
Gout
Autoinflammatory bone diseases:
CRMO (chronic recurrent multifocal osteomyelitis
SAPHO (synovitis, acne, pustulosis, hyperostosis, osteiitis)
What caused this disease to develop at this time?
PFAPA is an autoinflammatory, not autoimmune, disease and does not have a known trigger.
Due to inappropriate activation and regulation of antigen-independent inflammation (innate immunity).
What laboratory studies should you request to help confirm diagnosis? How should you interpret the results?
Initial screening tests:
CBC, differential during fever and when symptom-free
ESR, CRP during fever and when symptom-free
Complete metabolic panel
Uric acid, LD
Ferritin, fibrinoge.
Quantitative immunoglobulins (IgG, IgA, IgM)
Urinalysis
Blood, urine, throat cultures
PPD
Additional screening or diagnostic studies:
CMV, EBV, Brucella IgM & IgG
CMV, EBV DNA PCR
ANA panel, ANCA.
ACE (angiotensin converting enzyme)
C3, C4, C1 inhibitor activity
HLA typing (specifically for HLA B27, B51)
IgD
Interpretation of results:
Marked leukocytosis with left shift in association with ESR >80 and CRP >80 suggests an infectious process.
Positive PPD suggests tuberculosis.
Elevated uric acid or LD may suggest leukemic or other malignant process, particularly if associated with bone pain.
Hypogammaglobulinemia suggests infection secondary to primary immunodeficiency, while hypergammaglobulinemia suggests HIV or HIDS (hyper-immunoglobulinemia D with periodic fever).
Pertinent History:
Patients with PFAPA will have documented recurrent episodes of fever >38°C for at least 4-12 months WITHOUT concurrent infectious symptoms.
The patient's history should be explored for the following characteristics:
Peak fever temperature during the attacks
Pattern of fever (hectic, quotidian, recurrent, relapsing/periodic, continuous, intermittent, remittent)
Duration of fever
Antecedent or prodromal symptoms prior to onset of fever
Associated symptoms (rash, arthritis, diarrhea, etc)
Pattern of appearance of associated symptoms
Duration of associated symptoms
Predictability of symptoms and illness course
Duration of fever-free intervals
Overall health and persistent or chronic symptoms when afebrile
Famly history of similar febrile illnesses and response to treatment
Ethnicity of parents
Number and type of infections in lifetime and response to antibiotics
An alternative diagnosis should be suspected if the age of onset is >5 years, there is poor growth and/or development, there are persistent symptoms or laboratory abnormalities between attacks, or additional organ involvement beyond adenopathy and oral mucosal changes are noted.
Would imaging studies be helpful? If so, which ones?
Chest x-ray for infection, inflammatory lung disease, mass or serositis (pleuritis, pericarditis).
Chest, abdomen, pelvis computed tomography (CT) to evaluate lymphadenopathy, mass, inflammatory lung disease, serositis.
Bone gallium scan for osteomyelitis or tumor.
If you are able to confirm that the patient has PFAPA, what treatment should be initiated?
Are there some therapies that should be instituted immediately?
None
What about longer term treatment?
No treatment
Prednisone 1-2 mg/kg/day (max 60 mg) times 1-2 days at onset of symptoms
Consider cimetidine 20-40 mg/kg/day
Tonsillectomy (controversial as first line treatment)
What about alternative treatments if fails standard therapy?
Anakinra 1 mg/kg (max 100 mg) SQ within 48 hr of attack onset; may repeat once
Consider colchicine 0.3-1.2 mg daily
Tonsillectomy
What are the adverse effects associated with each treatment option?
Table I.
Adverse effects of treatment options
Corticosteroids | Infection, weight gain, muscle atrophy, adrenocortical insufficiency, osteopenia, growth delay, avascular necrosis, emotional lability, rash, edema, hypertension, diabetes |
Colchicine | Nausea, vomiting, diarrhea, abdominal pain, anorexia, peripheral neuropathy, muscle weakness, rhabdomyolysis, renal/liver toxicity, rash |
Anakinra | Infection, severe injection site reaction/pain, future malignancy |
Cimetidine | Headache, cytopenias |
Tonsillectomy | Pain/risks from surgery |
What are the possible outcomes of PFAPA?
What would you tell the family about prognosis?
Attacks end by 10 yr of age in almost all patients.
No long term complications and normal lifespan..
Normal growth and development.
What will you tell the family about risks/benefits of the available treatment options? (
Table II.
Risks and benefits of treatment options
Drug | Risks | Benefits |
---|---|---|
Corticosteroids | Adverse reactions; may shorten interval between or increase frequency of attacks in 30%. | Relieve fever, rash; improve adenopathy |
Colchicine | Adverse reactions; short-lived benefit in PFAPA | May reduce fever, oral aphthae; recurrences in 50% |
Anakinra | Adverse reactions; triggers flare of inflammation; no longlasting disease control off treatment | Remits fever, oral ulcers and laboratory abnomalities |
Cimetidine | Adverse reactions; no benefit in 50-70% pts | May reduce episodes of fever, pharyngitis, aphthous stomatitis, adenitis |
Tonsillectomy | Adverse reactions; recurrent PFAPA in 30% pts | Remits or decreases symptoms and attacks |
What causes PFAPA and how frequent is it?
Epidemiology:
No ethnic or geographic predominance.
55% affected are boys.
Incidence unknown, but not uncommon.
More common than hereditary PFS or cyclic neutropenia.
Genetics:
No gene defect(s) have been identified.
How do pathogens/genes/exposure cause the disease?
No known genetic predisposition or defined triggers for flares.
Other clinical manifestations that might help with diagnosis and management
None
What complications might you expect from the disease or treatment of the disease?
Complications are mild, brief and self-limited.
Treatment complications may be more common than from disease.
Are additional laboratory studies available; even some that are not widely available?
Consider genotyping for known inherited periodic fever syndromes to exclude these diagnoses.
How can PFAPA be prevented?
No known prevention.
What is the evidence?
Marshall, GS, Edwards, KM, Butler, J, Lawton, AR. "Syndrome of periodic fever, pharyngitis, and aphthous stomatitis". J Pediatr. vol. 110. 1987. pp. 43.
Thomas, KT, Feder, HM, Lawton, AR, Edwards, KM. "Periodic fever syndrome in children". J Pediatr. vol. 135. 1999. pp. 15.
Caorsi, R, Pelagatti, MA, Federici, S, Finetti, M, Martini, A, Gattorno, M. "Periodic fever, aphthous stomatitis, pharyngitis and adenitis syndrome". Curr Opin Rheumatol. vol. 22. 2010. pp. 579.
Burton, MJ, Polard, AJ, Ramsden, JD. "Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA)". Cochrance Database Syst Rev. 2010: Sep 8.
Gattorno, M, Caorsi, R, Meini, A, Cattalini, M, Federici, S, Zulian, F. "Differentiating PFAPA syndrome from monogenic periodic fevers". Pediatrics. vol. 124. 2009. pp. e721.
Caorsi, R, Pelagatti, MA, Federici, S, Finetti, M, Martini, A, Gattorno, M. "Periodic fever, apthous stomatitis, pharyngitis and adenitis syndrome". Curr Opin Rheumatol. vol. 22. 2010. pp. 579.
Stojanov, S, Lapidus, S, Chitkara, P, Feder, H, Salazar, JC, Fleisher, TA. "Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade". Proc Natl Acad Sci. April 8, 2011.
Ongoing controversies regarding etiology, diagnosis, treatment
Best management of PFAPA: steroids versus tonsillectomy versus IL-1 blockade versus no treatment.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
The Cardiology Advisor Articles
- The Connection Between Cardiovascular Disease and Sleep Apnea: An Expert Interview
- The Mounting Evidence Against Electronic Cigarette Use
- Entresto Significantly Improves Physical, Social Activity in Heart Failure Patients
- Nonpsychotic Cannabinoids in Hypertension: Benefits and Harms
- Clinical Case: Pregnant Woman Presents With Worsening Dyspnea
- Sacubitril/Valsartan vs Enalapril for Physical Activity Improvement in HFrEF
- Improved Outcomes With CABG vs PCI for Diabetes With LV Dysfunction
- Psoriasis Treatment Ixekizumab Safe for Cardiovascular Health
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Cardiovascular Complications of COPD